Beta Drugs Financial Statements
- Switch to
-
Tabular DataGraph
- Switch to
-
ConsolidatedStandalone
| Y/e 31 Mar | Mar-2020 | - | - | - |
|---|---|---|---|---|
| Growth matrix (%) | ||||
| Revenue growth | -- | -- | -- | -- |
| Op profit growth | -- | -- | -- | -- |
| EBIT growth | -- | -- | -- | -- |
| Net profit growth | -- | -- | -- | -- |
| Profitability ratios (%) | ||||
| OPM | 19.70 | -- | -- | -- |
| EBIT margin | 16 | -- | -- | -- |
| Net profit margin | 10.40 | -- | -- | -- |
| RoCE | -- | -- | -- | -- |
| RoNW | -- | -- | -- | -- |
| RoA | -- | -- | -- | -- |
| Per share ratios () | ||||
| EPS | 9.79 | -- | -- | -- |
| Dividend per share | -- | -- | -- | -- |
| Cash EPS | 5.88 | -- | -- | -- |
| Book value per share | 59.40 | -- | -- | -- |
| Valuation ratios | ||||
| P/E | 4.09 | -- | -- | -- |
| P/CEPS | 6.80 | -- | -- | -- |
| P/B | 0.67 | -- | -- | -- |
| EV/EBIDTA | 3.04 | -- | -- | -- |
| Payout (%) | ||||
| Dividend payout | -- | -- | -- | -- |
| Tax payout | (21) | -- | -- | -- |
| Liquidity ratios | ||||
| Debtor days | -- | -- | -- | -- |
| Inventory days | -- | -- | -- | -- |
| Creditor days | -- | -- | -- | -- |
| Leverage ratios | ||||
| Interest coverage | (5.60) | -- | -- | -- |
| Net debt / equity | 0.30 | -- | -- | -- |
| Net debt / op. profit | 0.96 | -- | -- | -- |
| Cost breakup () | ||||
| Material costs | (49) | -- | -- | -- |
| Employee costs | (10) | -- | -- | -- |
| Other costs | (21) | -- | -- | -- |
- Switch to
-
Tabular DataGraph
- Switch to
-
ConsolidatedStandalone
| Y/e 31 Mar( In .Cr) | Mar-2020 | - | - | - |
|---|---|---|---|---|
| Revenue | 90.80 | -- | -- | -- |
| yoy growth (%) | -- | -- | -- | -- |
| Raw materials | (44) | -- | -- | -- |
| As % of sales | 48.80 | -- | -- | -- |
| Employee costs | (9.50) | -- | -- | -- |
| As % of sales | 10.40 | -- | -- | -- |
| Other costs | (19) | -- | -- | -- |
| As % of sales | 21 | -- | -- | -- |
| Operating profit | 17.90 | -- | -- | -- |
| OPM | 19.70 | -- | -- | -- |
| Depreciation | (3.80) | -- | -- | -- |
| Interest expense | (2.60) | -- | -- | -- |
| Other income | 0.41 | -- | -- | -- |
| Profit before tax | 12 | -- | -- | -- |
| Taxes | (2.60) | -- | -- | -- |
| Tax rate | (21) | -- | -- | -- |
| Minorities and other | -- | -- | -- | -- |
| Adj. profit | 9.42 | -- | -- | -- |
| Exceptional items | -- | -- | -- | -- |
| Net profit | 9.42 | -- | -- | -- |
| yoy growth (%) | -- | -- | -- | -- |
| NPM | 10.40 | -- | -- | -- |
- Switch to
-
Tabular DataGraph
| Y/e 31 Mar ( In .Cr) | Mar-2020 | - | - | - |
|---|---|---|---|---|
| Profit before tax | 12 | -- | -- | -- |
| Depreciation | (3.80) | -- | -- | -- |
| Tax paid | (2.60) | -- | -- | -- |
| Working capital | -- | -- | -- | -- |
| Other operating items | -- | -- | -- | -- |
| Operating cashflow | -- | -- | -- | -- |
| Capital expenditure | -- | -- | -- | -- |
| Free cash flow | -- | -- | -- | -- |
| Equity raised | -- | -- | -- | -- |
| Investments | -- | -- | -- | -- |
| Debt financing/disposal | -- | -- | -- | -- |
| Dividends paid | -- | -- | -- | -- |
| Other items | -- | -- | -- | -- |
| Net in cash | -- | -- | -- | -- |
- Switch to
-
Tabular DataGraph
- Switch to
-
ConsolidatedStandalone
| Y/e 31 Mar ( In .Cr) | Mar-2020 | Mar-2019 | Mar-2018 | - |
|---|---|---|---|---|
| Equity capital | 9.61 | 8.65 | 8.65 | -- |
| Preference capital | -- | -- | -- | -- |
| Reserves | 47.50 | 32.30 | 24.20 | -- |
| Net worth | 57.10 | 40.90 | 32.90 | -- |
| Minority interest | ||||
| Debt | 22.60 | 20 | 7.50 | -- |
| Deferred tax liabilities (net) | 0.23 | 0.15 | 0.15 | -- |
| Total liabilities | 79.90 | 61 | 40.50 | -- |
| Fixed assets | 43.90 | 32.40 | 14.50 | -- |
| Intangible assets | ||||
| Investments | 0.35 | 0.35 | -- | -- |
| Deferred tax asset (net) | 0.40 | 0.29 | -- | -- |
| Net working capital | 29.90 | 24.70 | 14.10 | -- |
| Inventories | 12.40 | 9.53 | 2.80 | -- |
| Inventory Days | 49.60 | -- | -- | -- |
| Sundry debtors | 31.90 | 25 | 14.40 | -- |
| Debtor days | 128 | -- | -- | -- |
| Other current assets | 13.10 | 11.80 | 5.89 | -- |
| Sundry creditors | (16) | (16) | (6.10) | -- |
| Creditor days | 65.70 | -- | -- | -- |
| Other current liabilities | (11) | (6.10) | (3) | -- |
| Cash | 5.39 | 3.30 | 11.90 | -- |
| Total assets | 79.90 | 61 | 40.50 | -- |
- Switch to
-
ConsolidatedStandalone
| Beta Drugs Ltd Report not showing data |
|---|
